Gavin Cull

Crawley, WA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Journal: Internal medicine journal
Published: January 06, 2026

HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.

HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.

Journal: International journal of molecular sciences
Published: June 20, 2025

Incidence and outcomes of post-transplant lymphoproliferative disorder in the Western Australian liver transplant population: a 24-year retrospective study.

Incidence and outcomes of post-transplant lymphoproliferative disorder in the Western Australian liver transplant population: a 24-year retrospective study.

Journal: Internal medicine journal
Published: February 26, 2025

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Journal: Blood advances
Published: January 22, 2025

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.

Journal: Blood advances
Published: December 09, 2024

Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era.

Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era.

Journal: Leukemia & lymphoma
Published: October 18, 2024

Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.

Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.

Journal: Neuro-oncology
Published: December 01, 2023

Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.

Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.

Journal: Internal medicine journal
Published: November 15, 2023

How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

Journal: Blood cancer journal
Published: October 22, 2023

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 21, 2023

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.

Journal: Blood advances
Published: June 06, 2023

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.

Journal: Blood
Published: March 28, 2023
Showing 1-12 of 42

Last Updated: 09/26/2026